United States · Markets & Finance · The Motley Fool

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

Published by The Motley Fool · United States 8 h ago

Zepbound was a breakthrough. It became the first medicine to mimic the GLP-1 and GIP gut hormones and be approved for weight loss. Its main competitor, Wegovy, only mimics GLP-1.…

Read the full article on The Motley Fool Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Decrypt

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

CNBC

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

Share

Also worth reading

'Uptober' Starts Green as Bitcoin ETFs Draw $134 Million

Private Equity Firms Double Down on Fossil Fuels

American Airlines adds cash-and-miles bookings as loyalty battle heats up

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

This NYC startup requires 4 days in office but just let everyone work remote for a whole month